ArticleBreast (Edinburgh, Scotland)2026

Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.

Ayelet Shai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.